OBJECTIVES: The goal of this study is to analyze the cost of therapy for patients with chronic myeloid leukemia (CML) and their quality of life. METHODS: It is retrospective as regard to cost and prospective as regard to quality of life analysis. Five university hospitals in four major cities treating all 320 CML-patients are included for the period 2011-2012. Information is collected from the patients’ records about the health care resources used as medicines for CML, additional therapy, hospitalizations and physicians visits. The assessment of health related quality of life is conducted with validated for the country SF-36 questionnaire. RESULTS: 164 (51.2%) men and 156 (48.75%) women, average age 53.96±15.41 were observed. The average CML pharmacotherapy monthly cost is 5976.4 BGN, the average total pharmacotherapy cost for additional diseases is 566.27 BGN and the average additional costs for physicians’ visits and hospitalization is equal to 1504.69 BGN. The most expensive CML therapy is with Dasatinib 7771.20 BGN and the cheapest is Imatinib therapy equal to 5245.15 BGN. The most common additional diseases are cardiovascular (68%), followed by endocrine (29%). There is significant correlation between overall assessment for quality of life and average total additional costs – the higher assessment for QoL, the lower costs for hospitalization and visits. With the significantly highest score is the scale Bodily pain, followed by Physical functioning, and the lowest are Vitality, energy or fatigue and Role limitation. In most of patients on Imatinib (77.9%) are recorded good hematological responses and 66.7% are with major molecular response. CONCLUSIONS: CML is a disease consuming significant health care resources especially for major pharmacotherapy with TKIs. Infrequent physicians’ visits and rarer hospitalizations generate higher assessment of quality of life.